Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence
A partir de données portant sur 5 653 patients atteints d'un cancer de la vessie de stade localement avancé, cette étude évalue l'efficacité, du point de vue de la survie globale, de l'ajout d'une chimiothérapie adjuvante à une cystectomie
In the article that accompanies this editorial, Galsky et al use the National Cancer Data Base (NCDB) to examine the benefit associated with postcystectomy adjuvant chemotherapy for bladder cancer. A great deal of effort has been invested in optimizing the paradigm for perioperative chemotherapy in bladder cancer. In the neoadjuvant setting, two phase III studies have suggested an overall survival (OS) advantage with the use of cisplatin-based combination chemotherapy before cystectomy.
Journal of Clinical Oncology , éditorial en libre accès, 2016